Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

What is the purpose of this trial?

The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol dependence. Receptors are special molecules in the brain to which other molecules (neurotransmitters) attach during the normal every-day workings of the brain. Drugs can bind to those receptor molecules as well. Recent evidence suggests that kappa opioid receptors (KOR's) may play an important role in alcohol drinking behavior. This study will try to determine if naltrexone's ability to attach to these receptors is related to its effectiveness. We will use PET (positron emission tomography) for this study. PET is a type of imaging device found in nuclear medicine. It is used for tracking the presence of injected radioactive materials in the body.


Participation Guidelines

Ages: 21 - 50 years

Gender: Both


National Institute on Alcohol Abuse and Alcoholism

Dates: 12/19/2011 - 02/19/2016

Last Updated: 12/20/2017

Study HIC#: 1011007710

Get Involved

For more information about this study, contact:
Mark F. Dias
+1 203-737-6128
mark.dias@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image